Dag Aarsland

List of Publications by Citations

Source: https://exaly.com/author-pdf/628921/dag-aarsland-publications-by-citations.pdf

Version: 2024-04-02

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 547
papers
 38,105
citations
 90
h-index
 184
g-index

 630
ext. papers
 46,437
ext. citations
 5.8
avg, IF
 7.33
L-index

#	Paper	IF	Citations
547	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
546	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
545	Alzheimer's disease. <i>Lancet, The</i> , 2011 , 377, 1019-31	40	1645
544	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
543	Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. <i>Archives of Neurology</i> , 2003 , 60, 387-92		1081
542	Rivastigmine for dementia associated with Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2509-18	59.2	919
541	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
540	A systematic review of prevalence studies of depression in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 183-9; quiz 313	7	781
539	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019 , 51, 404-413	36.3	771
538	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
537	Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007 , 22, 2314-24	7	708
536	A systematic review of prevalence studies of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 1255-63	7	636
535	Dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2004 , 3, 19-28	24.1	560
534	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
533	Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. <i>Journal of the American Geriatrics Society</i> , 2000 , 48, 938-42	5.6	517
532	Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. <i>Movement Disorders</i> , 2006 , 21, 1343-9	7	471
531	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458

(2012-2009)

530	Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2175-86	7	376
529	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. <i>BMJ, The</i> , 2011 , 343, d4065	5.9	371
528	Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. <i>Movement Disorders</i> , 2007 , 22, 1061-8	7	371
527	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology, The</i> , 2009 , 8, 613-8	24.1	358
526	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. <i>Lancet Neurology, The</i> , 2012 , 11, 697-707	24.1	342
525	Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 617-26	7	339
524	Depression in Parkinson diseaseepidemiology, mechanisms and management. <i>Nature Reviews Neurology</i> , 2011 , 8, 35-47	15	338
523	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1123-30	7	320
522	Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. <i>Archives of Neurology</i> , 1999 , 56, 595-601		313
521	Lewy body dementias. <i>Lancet, The</i> , 2015 , 386, 1683-97	40	303
520	Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. <i>Annals of Neurology</i> , 2005 , 58, 773-6	9.4	280
519	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 18-22	3.2	276
518	Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. <i>Archives of Neurology</i> , 2004 , 61, 919-25		274
517	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 528-36	3.9	266
516	A 12-year population-based study of psychosis in Parkinson disease. <i>Archives of Neurology</i> , 2010 , 67, 996-1001		246
515	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1899-907	7	236
514	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015 , 47, 445-7	36.3	222
513	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012 , 8, 264-74	15	207

512	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimerg and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
511	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 254-9	5.5	202
510	Depression in dementia: epidemiology, mechanisms, and treatment. <i>Current Opinion in Psychiatry</i> , 2011 , 24, 461-72	4.9	198
509	Progression of motor impairment and disability in Parkinson disease: a population-based study. <i>Neurology</i> , 2005 , 65, 1436-41	6.5	196
508	The epidemiology of dementia associated with Parkinson's disease. <i>Brain Pathology</i> , 2010 , 20, 633-9	6	181
507	The rate of cognitive decline in Parkinson disease. <i>Archives of Neurology</i> , 2004 , 61, 1906-11		181
506	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
505	The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 78-84	3.9	173
504	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 81-95	15	165
503	Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. <i>PLoS ONE</i> , 2012 , 7, e37410	3.7	160
502	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. <i>NeuroImage: Clinical</i> , 2014 , 6, 115-25	5.3	158
501	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8754-9	11.5	158
500	Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 137-45	3.8	156
499	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012 , 259, 1639-47	5.5	153
498	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003 , 18, 937-41	3.9	153
497	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1080-6	5.5	151
496	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020 , 94, 743-	7 5 555	151
495	The association between motor subtypes and psychopathology in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 379-82	3.6	150

(2012-2008)

494	Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 445-52	2.6	145	
493	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 160-5	5.5	143	
492	Scales to assess psychosis in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 484-500	7	143	
49 ¹	Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. <i>Alzheimer Disease and Associated Disorders</i> , 2009 , 23, 295-7	2.5	142	
490	Neuropsychological profile of patients with Parkinson's disease without dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 15, 126-31	2.6	142	
489	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 661-9	3.9	137	
488	Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. <i>Neurology</i> , 2007 , 69, 747-54	6.5	135	
487	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010 , 14, 386-95	3.5	131	
486	Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005 , 18, 149-54	3.8	130	
485	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 504-514	4.6	128	
484	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014 , 82, 2017-25	6.5	122	
483	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 184-91	3.9	122	
482	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007 , 254, 38-45	5.5	118	
481	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010 , 25, 687-95	7	117	
480	Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 164-71	3.8	117	
479	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2017 , 16, 390-398	24.1	116	
478	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15	116	
477	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012 , 379, 528-36	40	116	

476	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015 , 25, 401-8	6	115
475	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014 , 26, 1083-98	3.4	109
474	Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1097-102	5.5	109
473	Risk factors for non-motor symptoms in Parkinson's disease. <i>Lancet Neurology, The</i> , 2018 , 17, 559-568	24.1	108
472	Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism and Related Disorders, 2009 , 15, 295-9	3.6	108
471	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015 , 20, 1588-95	15.1	107
470	The response of agitated behavior to pain management in persons with dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 708-17	6.5	106
469	Who suffers most? Dementia and pain in nursing home patients: a cross-sectional study. <i>Journal of the American Medical Directors Association</i> , 2008 , 9, 427-33	5.9	106
468	Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 42-9	2.7	104
467	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 371-7	3.9	101
466	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015 , 131, 2061-2069	16.7	100
465	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018 , 141, 582-595	11.2	100
464	Mild cognitive impairment in Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 371-8	6.6	100
463	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. <i>Neurobiology of Disease</i> , 2006 , 23, 481-9	7.5	99
462	Glial activation and inflammation along the Alzheimer's disease continuum. <i>Journal of Neuroinflammation</i> , 2019 , 16, 46	10.1	97
461	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2483-95	7	95
460	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 35-43	4.1	95
459	Association of Cerebral Amyloid-[Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94

(2011-2010)

458	Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 480-6	5.6	91	
457	Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006 , 21, 337-42	7	87	
456	A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 58-67	3.9	87	
455	The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005 , 20, 587-90	3.9	87	
454	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer</i> and Dementia, 2016 , 12, 1149-1158	1.2	86	
453	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 823-834	6.5	85	
452	Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S144-8	3.6	85	
451	Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2016 , 31, 1075-83	3.9	84	
450	The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. <i>PLoS ONE</i> , 2012 , 7, e45451	3.7	84	
449	Visual rating of white matter hyperintensities in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 22	3- 9	84	
448	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017 , 12, e0175674	3.7	84	
447	Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. <i>Journal of Alzheimer& Disease</i> , 2013 , 33, 723-36	4.3	80	
446	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 5	7.3	79	
445	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 Jears prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020 , 140, 267-278	14.3	79	
444	Neuropsychiatric symptoms in patients with multiple sclerosis. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 463-8	6.5	78	
443	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 431-8	4.3	76	
442	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014 , 35, 2836-2844	5.6	74	
441	Identification of novel ⊞ynuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <i>Neurochemical Research</i> , 2011 , 36, 2029-42	4.6	74	

440	The economic impact of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 15	54] -4	74
439	Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 252-8	3.9	74
438	Apathy in drug-nalle patients with incident Parkinson's disease: the Norwegian ParkWest study. Journal of Neurology, 2010 , 257, 217-23	5.5	73
437	Pain and its relationship to depression in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 269-75	6.5	72
436	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. <i>Neuropsychology</i> , 2011 , 25, 114-24	3.8	71
435	Dementia in Parkinson's disease. Current Opinion in Neurology, 2008, 21, 676-82	7.1	71
434	Pain treatment of agitation in patients with dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 1012-8	3.9	70
433	Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 392-8	3.9	69
432	Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Frontiers in Systems Neuroscience</i> , 2014 , 8, 45	3.5	69
431	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1064-8	5.5	68
430	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. <i>Human Brain Mapping</i> , 2015 , 36, 2980-95	5.9	67
429	The importance of pain management in older people with dementia. <i>British Medical Bulletin</i> , 2014 , 111, 139-48	5.4	67
428	Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. <i>Psychiatry and Clinical Neurosciences</i> , 2004 , 58, 343-7	6.2	66
427	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 628-36	3.9	64
426	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1809-15	7	62
425	Early and presenting symptoms of dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 202-8	2.6	62
424	Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. <i>European Journal of Pain</i> , 2014 , 18, 1490-500	3.7	61
423	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1581-7	2.9	61

(2017-2008)

422	Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled studythe Bergen District Nursing Home Study (BEDNURS). <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 889-95	3.9	60
421	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 201-7	6.5	60
420	The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 80-6	4.6	59
419	The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 703-717	3.9	58
418	Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 828-36	3.9	58
417	Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 633-7	4.6	57
416	A novel blood test for the early detection of Alzheimer's disease. <i>Journal of Alzheimer Disease</i> , 2011 , 23, 121-9	4.3	56
415	Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006 , 27, 433-8	5.6	56
414	Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1802-8	7	55
413	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 47	51.1	55
412	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimerg. Disease</i> , 2017 , 57, 787-795	4.3	54
411	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. <i>Journal of Internal Medicine</i> , 2014 , 275, 317-30	10.8	54
410	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. <i>NeuroImage</i> , 2009 , 47, 2083-9	7.9	54
409	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 265-284	15	53
408	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 1030-8	3.9	53
407	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimerg Disease</i> , 2017 , 59, 1139-1152	4.3	52
406	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 629	- 7 33	52
405	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. Journal of Neurology, Neurosurgery and Psychiatry, 2017 , 88, 325-331	5.5	51

404	Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson Disease</i> , 2015 , 5, 659-67	5.3	51
403	Neuropsychiatric symptoms in mild dementia with lewy bodies and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 34, 1-6	2.6	51
402	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009 , 21, 216-9	3.4	51
401	Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 374-9	2.7	51
400	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
399	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer Disease</i> , 2016 , 54, 287-95	4.3	50
398	Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 321-	. 3 1 ⁵	50
397	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. <i>Movement Disorders</i> , 2016 , 31, 1203-8	7	50
396	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 46-54	3.9	49
395	Grey matter changes in cognitively impaired Parkinson's disease patients. <i>PLoS ONE</i> , 2014 , 9, e85595	3.7	49
394	Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. <i>Neurobiology of Aging</i> , 2010 , 31, 104-13	5.6	49
393	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005 , 112, 386-90	3.8	49
392	Prevalence of late-life depression and gap in mental health service use across European regions. <i>European Psychiatry</i> , 2019 , 57, 19-25	6	48
391	Cerebrospinal fluid amyloid-land phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013 , 84, 537-43	5.5	48
390	Executive dysfunction in mild cognitive impairment is associated with changes in frontal and cingulate white matter tracts. <i>Journal of Alzheimerg Disease</i> , 2011 , 27, 453-62	4.3	48
389	Neuropsychiatric aspects of Parkinson's disease. <i>Current Psychiatry Reports</i> , 1999 , 1, 61-8	9.1	48
388	Donepezil for dementia with Lewy bodies: a case study 1999 , 14, 69-72		48
387	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021 , 33, 505-514	3.4	48

(2015-2021)

386	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimerg</i> and Dementia, 2021 , 17, 1145-1156	1.2	48
385	Apolipoprotein E 🛭 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1227-31	5.5	47
384	Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 621-4	3.6	47
383	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017 , 55, 143-158	5.6	46
382	Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples. <i>Age and Ageing</i> , 2016 , 45, 54-60	3	46
381	Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. <i>CNS Neuroscience and Therapeutics</i> , 2011 , 17, 428-41	6.8	46
380	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016 , 139 Suppl 1, 290-317	6	45
379	Health and well-being in care staff and their relations to organizational and psychosocial factors, care staff and resident factors in nursing homes. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 789-97	3.9	45
378	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
377	High prevalence of orthostatic hypotension in mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 307-13	2.6	44
376	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020 , 16, 661-673	315	44
375	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1361-1369	3.9	43
374	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 297-301	7	43
373	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. <i>Acta Neurologica Scandinavica</i> , 2010 , 122, 418-24	3.8	43
372	MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 13	5.3	42
371	Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 161-9	2.6	42
370	APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009 , 22, 166-70	3.8	42
369	Amyloid-land Bynuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 758-64	3.6	41

368	The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 381-8	6.5	41
367	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016 , 6, e010357	3	41
366	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 559-63	2.6	40
365	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021 , 53, 1276-1282	36.3	40
364	COSMOSimproving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015 , 10, 131	8.4	38
363	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ Open</i> , 2014 , 4, e005158	3	38
362	Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 48-56	2.5	38
361	CSF amyloid B8 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 160-4	5.5	38
360	Depressive symptoms in Alzheimer's disease and lewy body dementia: a one-year follow-up study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 143-9	2.6	38
359	The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. <i>International Psychogeriatrics</i> , 2012 , 24, 1771-8	3.4	38
358	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014 , 29, 651-62	7	37
357	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020 , 32, 705-717	3.4	37
356	Prevalence of the apolipoprotein E A allele in amyloid positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimers and Dementia</i> , 2018 , 14, 913-924	1.2	36
355	Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. <i>Drugs and Aging</i> , 2013 , 30, 603-1	1 ^{4·7}	36
354	Nonlinear decline of mini-mental state examination in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 334-7	7	36
353	EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. <i>Journal of Alzheimerg</i> Disease, 2016 , 54, 1649-1657	4.3	36
352	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimerg and Dementia</i> , 2019 , 15, 400-409	1.2	36
351	Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012 , 12, 492-501	6.6	35

350	Amyloid-Land Parkinson's disease. <i>Journal of Neurology</i> , 2019 , 266, 2605-2619	5.5	35
349	Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 930-5	5.5	34
348	Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. <i>Journal of Neurology</i> , 2013 , 260, 1104-15	5.5	34
347	Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 227-34	2.6	34
346	Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 330-8	2.6	34
345	Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 34, 44-50	2.6	33
344	Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. <i>Journal of the Neurological Sciences</i> , 2012 , 322, 211-6	3.2	33
343	Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 291-300	2.5	33
342	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020 , 216, 43-48	5.4	33
341	Neuropsychiatric symptoms in dementia-a role for neuroinflammation?. <i>Brain Research Bulletin</i> , 2014 , 108, 88-93	3.9	32
340	Mapping cortical atrophy in Parkinson's disease patients with dementia. <i>Journal of Parkinsong Disease</i> , 2013 , 3, 69-76	5.3	32
339	Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 725-31	3.9	32
338	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016 , 42, 352-65	5.2	32
337	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019 , 50, 72-80	12	32
336	Associations between pain and depression in nursing home patients at different stages of dementia. <i>Journal of Affective Disorders</i> , 2017 , 218, 8-14	6.6	31
335	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson Disease</i> , 2015 , 5, 783-92	5.3	31
334	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. <i>BMJ Open</i> , 2014 , 4, e003976	3	31
333	Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1084-90	5	31

332	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 330-339	5.9	31
331	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
330	Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017 , 7, 283-296	2.5	30
329	Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 141-8	6.5	30
328	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 247-268	4.3	30
327	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018 , 65, 18-40	5.6	30
326	Synaptic proteins in CSF relate to Parkinson's disease stage markers. <i>Npj Parkinson Disease</i> , 2017 , 3, 7	9.7	30
325	Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2020 , 26, 803-818	11.5	30
324	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimers and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 143-15	2 ^{5.2}	29
323	Higher Frequency and Complexity of Sleep Disturbances in Dementia with Lewy Bodies as Compared to Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016 , 16, 152-60	2.3	29
322	Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: an MRI surface-based morphometric study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 4-13.e1	6.5	29
321	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B:</i> Neuropsychiatric Genetics, 2018, 177, 232-241	3.5	28
320	Personality changes after deep brain stimulation in Parkinson's disease. <i>Parkinsong Disease</i> , 2015 , 2015, 490507	2.6	28
319	Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 195-205	2.6	28
318	FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007 , 20, 89-92	3.8	28
317	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 430-440	6.5	28
316	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019 , 85, 715-725	9.4	27
315	Mental health of people living with dementia in care homes during COVID-19 pandemic. <i>International Psychogeriatrics</i> , 2020 , 32, 1253-1254	3.4	27

314	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019 , 29, 63-74	6	27	
313	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. International Journal of Geriatric Psychiatry, 2011, 26, 1054-61	3.9	27	
312	New insights into the genetic etiology of Alzheimer's disease and related dementias <i>Nature Genetics</i> , 2022 ,	36.3	27	
311	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimer Disease</i> , 2017 , 59, 339-358	4.3	26	
310	Neuroanatomical correlates of late-life depression and associated cognitive changes. <i>Neurobiology of Aging</i> , 2015 , 36, 3090-3099	5.6	26	
309	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020 , 66, 101714	15.4	26	
308	A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer's disease. <i>Alzheimer Research and Therapy</i> , 2016 , 8, 3	9	26	
307	Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. <i>Acta Psychiatrica Scandinavica</i> , 2011 , 123, 459-65	6.5	26	
306	The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). <i>International Journal of Palliative Nursing</i> , 2011 , 17, 420, 422, 424	0.9	26	
305	White matter hyperintensities and the course of depressive symptoms in elderly people with mild dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 97-111	2.5	26	
304	Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 335-43	2.5	25	
303	Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. <i>Scientific Reports</i> , 2018 , 8, 18088	4.9	25	
302	GBA and APOE A associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019 , 9, 7013	4.9	24	
301	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinsong Disease</i> , 2019 , 5, 7	9.7	24	
300	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 927-35	3.1	24	
299	Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 824-9	7	24	
298	Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 183-6	3.6	24	
297	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018 , 13, 935-946	4	24	

296	Detecting At-Risk Alzheimer's Disease Cases. Journal of Alzheimer Disease, 2017, 60, 97-105	4.3	23
295	Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. <i>International Psychogeriatrics</i> , 2018 , 30, 395-407	3.4	23
294	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. <i>Neurobiology of Aging</i> , 2016 , 42, 124-31	5.6	23
293	New Therapeutic Strategies for Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 68	6.6	23
292	Classifying dementia using local binary patterns from different regions in magnetic resonance images. <i>International Journal of Biomedical Imaging</i> , 2015 , 2015, 572567	5.2	23
291	Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015 , 5, 212-20	2.5	23
290	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020 , 11, 579934	5	23
289	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
288	Psychosis in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 585-622	4.4	22
287	Familial Parkinson's disease: a community-based study. European Journal of Neurology, 2003, 10, 159-63	6	22
287	Familial Parkinson's disease: a community-based study. <i>European Journal of Neurology</i> , 2003 , 10, 159-63. Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 2110-2118	6.9	22
Í	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> ,		
286	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 2110-2118 Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies.	6.9	22
286	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 2110-2118 Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016 , 31, 118-25 Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> ,	6.9 7	22
286 285 284	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 2110-2118 Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016 , 31, 118-25 Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018 , 32, 621-635 Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> ,	6.9 7 6.7	22 22 21
286 285 284 283	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2110-2118 Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016, 31, 118-25 Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 621-635 Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964 Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of</i>	6.9 7 6.7 3.7	22 22 21 21
286 285 284 283	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2110-2118 Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016, 31, 118-25 Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 621-635 Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964 Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 275-294 Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. <i>Alzheimers</i>	6.9 7 6.7 3.7 4.4	22 22 21 21 21

(2020-2020)

278	Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020 , 14, 716	5.1	20	
277	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with Eamyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016 , 9, 84	4.5	20	
276	Mild cognitive impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021 , 50, 72-80	3	20	
275	Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 183-192	3.9	19	
274	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 202-210	3.6	19	
273	Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. <i>Movement Disorders</i> , 2006 , 21, 2170-4	7	19	
272	Familial occurrence of dementia and parkinsonism: a systematic review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 288-95	2.6	19	
271	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020 , 35, 595-605	7	19	
270	SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics. <i>Scientific Reports</i> , 2017 , 7, 41929	4.9	18	
269	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. <i>Translational Psychiatry</i> , 2019 , 9, 273	8.6	18	
268	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. Journal of Alzheimers Disease, 2016, 50, 101-10	4.3	18	
267	Neurobiological correlates of depressive symptoms in people with subjective and mildæognitive impairment. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 131, 139-47	6.5	18	
266	A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 31	5.9 6-22	18	
265	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. <i>Alzheimer Research and Therapy</i> , 2014 , 6, 53	9	18	
264	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 206-13	3.9	18	
263	Core and suggestive symptoms of dementia with lewy bodies cluster in persons with mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 317-24	2.6	18	
262	EAmyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020 , 95, e3257-e3268	6.5	18	
261	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18	

260	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. <i>Advances in Neurology</i> , 2005 , 96, 56-64		18
259	Increased Transforming Growth Factor 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A 2 Load. <i>Journal of Alzheimer Disease</i> , 2017 , 56, 157-166	4.3	17
258	Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019 , 9, 176-183	2.5	17
257	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018 , 35, 545-558	4:7	17
256	Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. <i>Journal of Alzheimer Disease</i> , 2015 , 47, 523-9	4.3	17
255	Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. <i>American Journal of Alzheimer& Disease and Other Dementias</i> , 2010 , 25, 407-13	2.5	17
254	Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. <i>Journal of Alzheimer</i> Disease, 2010 , 20, 301-11	4.3	17
253	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer[s disease. <i>Alzheimer Research and Therapy</i> , 2014 , 6, 53	9	17
252	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020 , 95, 26-45	5.6	17
251	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 75-86	6.5	17
250	Cerebrospinal fluid neurogranin/Esite APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 617-627	6	17
249	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018 , 33, 528-536	7	16
248	Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study. <i>Npj Parkinson Disease</i> , 2016 , 2, 15030	9.7	16
247	Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 573-82	3.9	16
246	Cerebrospinal Fluid Levels of sAPPland sAPPlan Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimerg Disease</i> , 2011 , 2011, 495025	3.7	16
245	A pilot study examining associations between DYRK1A and Bynuclein dementias. <i>Neurodegenerative Diseases</i> , 2012 , 10, 229-31	2.3	16
244	Grey matter atrophy in early versus late dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 620-5	3.6	16
243	Management of Parkinson's disease dementia: practical considerations. <i>Drugs and Aging</i> , 2006 , 23, 807	-2427	16

242	Lexical and nonlexical spelling deficits in dementia of the Alzheimer type. <i>Brain and Language</i> , 1996 , 52, 551-63	2.9	16	
241	Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 821-7	5.9	16	
240	Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia. <i>Journal of Alzheimerg Disease</i> , 2017 , 56, 575-584	4.3	15	
239	Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 700-713	5.3	15	
238	Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management. <i>Current Neurology and Neuroscience Reports</i> , 2005 , 5, 345-54	6.6	15	
237	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020 , 9, 36	10.3	15	
236	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 604-609	5.9	15	
235	Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years. <i>Journal of Parkinson Disease</i> , 2018 , 8, S107-S113	5.3	15	
234	Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. <i>CNS Drugs</i> , 2019 , 33, 143-160	6.7	14	
233	Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without Alzheimer disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 40-8	3.8	14	
232	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016 , 87, 1045-51	6.5	14	
231	alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010 , 22, 321-7	3.4	14	
230	Subthreshold depression in patients with Parkinson's disease and dementiaclinical and demographic correlates. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 980-5	3.9	14	
229	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer& Disease</i> , 2017 , 57, 373-386	4.3	13	
228	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020 , 91, 88-111	5.6	13	
227	Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 580-6	6.5	13	
226	ASSOCIATION OF DEPRESSIVE SYMPTOMS AND SUBJECTIVE MEMORY COMPLAINTS WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER ADULTS WITH HIGH BLOOD PRESSURE. <i>European Geriatric Medicine</i> , 2019 , 10, 413-420	3	12	
225	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. <i>Journal of Neural Transmission</i> , 2019 , 126, 327-337	4.3	12	

224	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014 , 3, 108	3.6	12
223	Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimer∃ disease risk		12
222	Trajectories of depressive symptoms and associated patterns of cognitive decline. <i>Scientific Reports</i> , 2020 , 10, 20888	4.9	12
221	Association of Butyrylcholinesterase-K Allele and Apolipoprotein E e4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer</i> Disease, 2016 , 50, 567-76	4.3	12
220	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 38-46	3.9	12
219	Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2021 , 268, 2769-2779	5.5	12
218	Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimer</i> and <i>Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12164	5.2	12
217	Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. <i>Journal of Alzheimer Disease</i> , 2016 , 53, 621-30	4.3	11
216	Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 234-44	2.6	11
215	Mania after administration of cholinesterase inhibitors in patients with dementia and comorbid bipolar disorder: two case reports. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 254-6	1.7	11
214	Depression in Parkinson's disease. <i>Acta Psychiatrica Scandinavica</i> , 2002 , 106, 161-2	6.5	11
213	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018 , 15, 883-891	3	11
212	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2257-2263	5.6	11
211	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 464.e1-7	5.9	11
210	Mediating effect of mutuality on caregiver burden in Parkinson's disease partners. <i>Aging and Mental Health</i> , 2020 , 24, 1421-1428	3.5	11
209	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. <i>Neuroscience Letters</i> , 2015 , 594, 137-43	3.3	10
208	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745	4.9	10
207	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 520-527	7	10

206	Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. <i>Alzheimerg Research and Therapy</i> , 2018 , 10, 83	9	10
205	Person-centred care and care mapping in dementia. Lancet Neurology, The, 2009, 8, 302-3	24.1	10
204	Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. <i>Neuropathology and Applied Neurobiology</i> , 2007 , 33, 586-90	5.2	10
203	Psychiatric aspects of Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2005 , 18, 335-41	4.9	10
202	The neuropsychiatry of Parkinson's disease: advances and challenges <i>Lancet Neurology, The</i> , 2022 , 21, 89-102	24.1	10
201	Psychosis in Alzheimer's Disease. Current Neurology and Neuroscience Reports, 2020 , 20, 57	6.6	10
200	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimer Research and Therapy</i> , 2021 , 13, 89	9	10
199	Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. <i>Journal of Alzheimerg Disease</i> , 2016 , 53, 1277-85	4.3	10
198	Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. Journal of Geriatric Physical Therapy, 2019 , 42, E122-E128	3.2	10
197	Patterns of carer distress over time in mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 987-993	3.9	9
196	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 728-730	5.5	9
195	Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinson's Disease and Their Spouses. <i>Parkinsong Disease</i> , 2017 , 2017, 4697052	2.6	9
194	Relationship between orthostatic hypotension and white matter hyperintensity load in older patients with mild dementia. <i>PLoS ONE</i> , 2012 , 7, e52196	3.7	9
193	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum <i>JAMA Neurology</i> , 2022 ,	17.2	9
192	The combined effect of amyloid-land tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020 , 27, 102333	5.3	9
191	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 413-21	5.3	9
190	Montreal Cognitive Assessment in a 63- to 65-year-old Norwegian Cohort from the General Population: Data from the Akershus Cardiac Examination 1950 Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017 , 7, 318-327	2.5	9
189	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer</i> Disease, 2017 , 57, 387-393	4.3	8

188	Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies. <i>Journal of Alzheimerg Disease</i> , 2019 , 67, 995-1005	4.3	8
187	Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia - A Pilot Study. <i>Frontiers in Genetics</i> , 2019 , 10, 536	4.5	8
186	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. <i>International Journal of Tryptophan Research</i> , 2019 , 12, 1178646919877883	5.6	8
185	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. <i>Npj Genomic Medicine</i> , 2017 , 2, 24	6.2	8
184	Psychometric properties of the mutuality scale in Swedish dyads with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 122-128	3.8	8
183	Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. <i>Biomedical Signal Processing and Control</i> , 2017 , 33, 19-29	4.9	8
182	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 32-36	2.2	8
181	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021 , 36, 89-101	12.1	8
180	Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 917-925	3.9	8
179	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinsong Disease</i> , 2021 , 11, 1209-1219	5.3	8
178	Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimerg Disease</i> , 2017 , 59, 929-939	4.3	7
177	A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 124	4.1	7
176	Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 281-90	2.5	7
175	Association of Malnutrition with Functional and Cognitive Trajectories in People Living with Dementia: A Five-Year Follow-Up Study. <i>Journal of Alzheimer& Disease</i> , 2021 , 79, 1713-1722	4.3	7
174	Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: A Longitudinal Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1108-1113	5.9	6
173	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer& Disease</i> , 2016 , 53, 349-61	4.3	6
172	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer</i> Disease, 2018 , 64, 761-774	4.3	6
171	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> 2017 44 283-293	2.6	6

(2021-2017)

170	Screening for Alzheimer's Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients. <i>Journal of Alzheimer& Disease</i> , 2017 , 60, 1621-1631	4.3	6
169	Are anxiety disorders undertreated in patients with multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 372-3		6
168	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. <i>Programme Grants for Applied Research</i> , 2020 , 8, 1-98	1.5	6
167	Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. Journal of Alzheimer Disease, 2020 , 73, 1321-1330	4.3	6
166	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. <i>Scientific Reports</i> , 2019 , 9, 17222	4.9	6
165	The association between aspects of carer distress and time until nursing home admission in persons with Alzheimer's disease and dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2021 , 33, 337-345	3.4	6
164	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson</i> Disease, 2021 , 11, 299-307	5.3	6
163	The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 1421-1428	3.9	5
162	REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild Dementia. <i>Frontiers in Neurology</i> , 2017 , 8, 375	4.1	5
161	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012 , 531, 1-4	3.3	5
160	Cognitive and psychiatric disturbances in Parkinson disease. Aging Health, 2011, 7, 123-142		5
159	Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities <i>Nature Reviews Neurology</i> , 2022 ,	15	5
158	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1143-1155	4.3	5
157	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
156	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021 , 1	8.8	5
155	In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimerg Disease</i> , 2019 , 67, 715-723	4.3	5
154	Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia. <i>Frontiers in Psychiatry</i> , 2021 , 12, 706695	5	5
153	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimerg Disease</i> , 2021 , 82, 913-919	4.3	5

152	Polypharmacy is associated with functional decline in Alzheimer's disease and Lewy body dementia. <i>Archives of Gerontology and Geriatrics</i> , 2021 , 96, 104459	4	5
151	[P3017]: HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES 2017 , 13, P936		4
150	Harnessing the power of cohort studies for dementia research. <i>Journal of Public Mental Health</i> , 2015 , 14, 8-17	0.7	4
149	Biomarkers of PD progression: is CSF the answer?. <i>Neurology</i> , 2010 , 75, 1036-7	6.5	4
148	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2021 ,	17.2	4
147	Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study. <i>Frontiers in Psychiatry</i> , 2020 , 11, 582207	5	4
146	Resting-state EEG alpha/theta ratio related to neuropsychological test performance in Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2021 , 132, 756-764	4.3	4
145	The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 932-940	3.9	4
144	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2020 , 91, 109-110	5.5	4
143	Association between physical activity and cognition in Mexican and Korean older adults. <i>Archives of Gerontology and Geriatrics</i> , 2020 , 89, 104047	4	4
142	Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1162-1174	7.3	4
141	Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinson's Disease. <i>Parkinsong Disease</i> , 2018 , 2018, 9548681	2.6	4
140	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020 , 13, 641-654	5.1	4
139	A new tool to identify patients with Parkinson's disease at increased risk of dementia. <i>Lancet Neurology, The</i> , 2017 , 16, 576-578	24.1	3
138	Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary care. <i>BMJ Open</i> , 2020 , 10, e035147	3	3
137	Persistence and Prognostic Implications of Orthostatic Hypotension in Older Individuals with Mild-to-Moderate Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 283-96	2.5	3
136	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014 , 121, 71-8	4.3	3
135	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004 , 3, 397-412		3

(2021-2016)

134	Isoelectric point region pla.4 as a treasure island of abnormal proteoforms in blood. <i>Discoveries</i> , 2016 , 4, e67	3.7	3
133	Hippocampal subfields and decline in activities of daily living in Alzheimer's disease and dementia with Lewy bodies. <i>Neurodegenerative Disease Management</i> , 2020 , 10, 357-367	2.8	3
132	A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1471-1487	3.9	3
131	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson</i> Disease, 2016 , 6, 733-739	5.3	3
130	An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimerg</i> and Dementia: Translational Research and Clinical Interventions, 2021 , 7, e12171	6	3
129	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project. <i>Alzheimerg and Dementia</i> , 2021 , 17, 1277-1286	1.2	3
128	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. Journal of Alzheimer& Disease, 2022, 1-11	4.3	3
127	Plasma p-tau181 accurately predicts Alzheimer disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer and Dementia</i> , 2020 , 16, e047539	1.2	2
126	Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease. <i>Brain Sciences</i> , 2020 , 10,	3.4	2
125	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review [] CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014 , 26, 1099-1099	3.4	2
124	O5-03-04: Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort 2015 , 11, P320-P320		2
123	Impulse control disorders and related behaviors140-152		2
122	Neuropsychiatric and cognitive disorders in other parkinsonian disorders261-274		2
121	Components of the choline oxidation pathway modify the association between the apolipoprotein gene variant and cognitive decline in patients with dementia. <i>Brain Research</i> , 2020 , 1726, 146519	3.7	2
120	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimerg Research and Therapy</i> , 2020 , 12, 153	9	2
119	Psychiatric and neuropsychiatric syndromes and COVID-19. <i>Lancet Psychiatry,the</i> , 2020 , 7, 663-664	23.3	2
118	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021 , 76, 1726-1737	4.6	2
117	Presynaptic accumulation of Bynuclein causes synaptopathy and progressive neurodegeneration in. <i>Brain Communications</i> , 2021 , 3, fcab049	4.5	2

116	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021 , 56, 70-85	2.3	2
115	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223	4.5	2
114	P3-554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATION-BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY 2018 , 14, P1335-P1335		2
113	Muscle volume and intramuscular fat of the tongue evaluated with MRI predict malnutrition in people living with dementia: a five-year follow-up study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 ,	6.4	2
112	Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia. <i>International Psychogeriatrics</i> , 2021 , 33, 1217-1228	3.4	2
111	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. Journal of Alzheimer Disease, 2021 , 83, 1825-1839	4.3	2
110	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021 , 105, 252-261	5.6	2
109	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report <i>Frontiers in Neurology</i> , 2022 , 13, 839539	4.1	2
108	Lewy Body Dementias. Focus (American Psychiatric Publishing), 2017, 15, 85-100	1.1	1
107	Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. Journal of Alzheimer& Disease, 2019, 68, 239-253	4.3	1
106	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039139	1.2	1
105	The ANeED study: Ambroxol in new and early dementia with Lewy bodies. <i>Alzheimerg</i> and Dementia , 2020 , 16, e042589	1.2	1
104	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson and Lewy body diseases. <i>Alzheimer and Dementia</i> , 2020 , 16, e045886	1.2	1
103	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimergs and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12098	5.2	1
102	Colombian consortium for the study of Lewy body dementia COL-DLB. <i>Journal of the Neurological Sciences</i> , 2020 , 412, 116807	3.2	1
101	Risk of Hospitalization in Patients with Alzheimer's Disease and Lewy Body Dementia: Time to and Length of Stay. <i>Journal of Alzheimer Disease</i> , 2020 , 74, 1221-1230	4.3	1
100	A 5-YEAR LONGITUDINAL STUDY OF PATIENTS WITH DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE 2014 , 10, P261-P261		1
99	O3🛮 0 🗗 1: Clinical course of Lewy-body disease: Cognitive decline and mortality 2013 , 9, P537-P538		1

98	[P1099]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE 2017 , 13, P367-P367	1
97	[P1B64]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES 2017 , 13, P510-P511	1
96	Nonmotor symptoms of Parkinson's disease. <i>Parkinson's Disease</i> , 2011 , 2011, 351461 2.6	1
95	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006 , 2, 461-472	1
94	Rivastigmine in Parkinson Disease Dementia. CNS Drugs, 2006, 20, 748-750 6.7	1
93	Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia. <i>Neuropsychology</i> , 2020 , 34, 851-861	1
92	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology <i>Journal of Neurology</i> , 2022 , 1	1
91	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts British Journal of Psychiatry, 2022, 1-10 5-4	1
90	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2021 , 152, 10525†-4	1
89	Risky drinking and cognitive impairment in community residents aged 50 and bver. <i>Aging and Mental Health</i> , 2021 , 1-8	1
88	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1117-1127	1
87	Body mass index, performance on activities of daily living and cognition: analysis in two different populations. <i>BMC Geriatrics</i> , 2021 , 21, 177	1
86	Plasma Neurofilament Light Chain predicts cognitive progression in prodromal and clinical dementia with Lewy Bodies	1
85	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021 , 11, e02086	1
84	Regression-based norms for the FAS phonemic fluency test for ages 40-84 based on a Norwegian sample. <i>Applied Neuropsychology Adult</i> , 2021 , 1-10	1
83	Commentary: A posterior-to-anterior shift of brain functional dynamics in aging. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 341	1
82	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimerg and Dementia: Diagnosis,</i> 5.2 Assessment and Disease Monitoring, 2021 , 13, e12235	1
81	P1-658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS 2018 , 14, P595-P595	1

8o	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021 , 106, 304.e1-304.e3	5.6	1
79	Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. <i>Alzheimerg and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12152	5.2	1
78	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography Journal of Neuropsychiatry and Clinical Neurosciences, 2022, appineuropsych21050135	2.7	1
77	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer and Dementia</i> , 2020 , 16, e041	8 0 8	О
76	Psychiatric Aspects of Parkinson Disease, Parkinson Disease with Dementia, and Dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 111-111	3.8	О
75	Psychiatric issues in non-Alzheimer dementias. Clinical Neuroscience Research, 2004, 3, 397-397		О
74	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data <i>Alzheimerg Research and Therapy</i> , 2022 , 14, 14	9	О
73	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021 , 11, 20375	4.9	О
72	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 916	4.1	O
71	Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2021 , 12, 679984	4.1	O
70	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 573-584	6.5	O
69	Serum tyrosine is associated with better cognition in Lewy body dementia. <i>Brain Research</i> , 2021 , 1765, 147481	3.7	O
68	Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness <i>Dementia and Geriatric Cognitive Disorders</i> , 2022 , 1-10	2.6	О
67	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases <i>Neurobiology of Aging</i> , 2022 , 115, 88-108	5.6	O
66	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations Translational Neurodegeneration, 2022 , 11, 24	10.3	O
65	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis <i>Journal of Affective Disorders</i> , 2022 , 309, 437-445	6.6	O
64	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020 , 11, 602480	5	
63	Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines. <i>Alzheimerg</i> and Dementia, 2020 , 16, e037636	1.2	

62	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039145	1.2
61	Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care. <i>Alzheimerg</i> and Dementia, 2020 , 16, e039147	1.2
60	Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients. <i>Alzheimer</i> and Dementia, 2020 , 16, e039231	1.2
59	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer disease dementia and Lewy body dementia. <i>Alzheimer and Dementia</i> , 2020 , 16, e041881	1.2
58	A systematic review on the physical and mental health risk factors of mild cognitive impairment and Alzheimer disease in military veterans. <i>Alzheimer and Dementia</i> , 2020 , 16, e042913	1.2
57	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimerg and Dementia</i> , 2020 , 16, e043593	1.2
56	A prospective long-term study of TDP-43 pathology in Alzheimer disease aggression. <i>Alzheimer gand Dementia</i> , 2020 , 16, e043659	1.2
55	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. <i>Alzheimer</i> and <i>Dementia</i> , 2020 , 16, e043789	1.2
54	Functional alterations in visual networks underlie differences in the phenomenology of visual hallucinations in Lewy body disease. <i>Alzheimerg and Dementia</i> , 2020 , 16, e045102	1.2
53	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson and Lewy body diseases. <i>Alzheimer</i> and <i>Dementia</i> , 2020 , 16, e045811	1.2
52	Plasma-based biomarkers for Aland tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer disease. <i>Alzheimer and Dementia</i> , 2020 , 16, e046490	1.2
51	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer</i> and Dementia, 2020 , 16, e042969	1.2
50	P2-135: CSF a½2 is related to cortical metabolism (FDG-PET) in non-demented parkinson's disease patients 2015 , 11, P536-P537	
49	[P1Ø35]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUB-UNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS 2017 , 13, P333-P334	
48	[P3043]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY 2017 , 13, P1033-P1033	
47	[P4🛮54]: DETECTING AT-RISK CASES FOR ALZHEIMER's DISEASE 2017 , 13, P1317-P1317	
46	[P1월56]: INCREASED PSER129	
45	[P2I04]: RPT6, 20S & AND B PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS 2017 , 13, P684-P684	

44	[F50103]: CLINICO-PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND TREATMENT 2017 , 13, P1444-P1445
43	Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al. <i>Movement Disorders</i> , 2015 , 30, 1711
42	Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management1-13
41	Parkinsonඕ disease: pathology, anatomy, and behavior14-24
40	The boundaries of Parkinson disease dementia and dementia with Lewy bodies 40-52
39	Cognitive assessment in Parkinson disease 53-64
38	Clinical assessment: mood and motivation65-72
37	Imaging and behavior in Parkinson⊞ disease: structural imaging73-88
36	Imaging and behavior in Parkinson disease: functional imaging 89-96
35	Diagnosis and biomarkers: CSF97-108
34	Apathy131-139
33	Psychosis153-162
32	Early cognitive impairment163-176
31	Parkinson disease dementia 177-191
30	Sleep disturbances192-210
29	Surgical treatment and behavior230-243
28	Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model244-254
27	The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease255-260

Neuropsychiatric aspects of the on/off phenomenon275-284 26 Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies285-291 25 The genetics of behavior and cognition in Parkinson disease 25-39 24 Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. 2.8 23 Neurodegenerative Disease Management, 2013, 3, 105-107 Man with fluctuating confusion 148-154 22 Journal Wach: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. 2.8 21 Neurodegenerative Disease Management, 2011, 1, 187-189 Reply: Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 2011, 26, 191-192 20 7 Rivastigmine for the treatment of Parkinson disease dementia. Aging Health, 2010, 6, 277-284 19 Clinical aspects of Parkinson dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G 18 3 W Bruyn, 2008, 89, 303-6 Basal ganglia diseases and geriatric psychiatry: a new approach. Current Opinion in Psychiatry, 2003, 17 4.9 16, 621-627 Role of Neuropsychiatric Assessment in Diagnosis and Research 2005, 163-183 16 Tongue muscle mass is associated with total grey matter and hippocampal volumes in Dementia 4 with Lewy Bodies.. Archives of Gerontology and Geriatrics, 2022, 100, 104647 Actions to be taken for improving functional prognosis in dementia.. Journal of the Neurological 14 3.2 Sciences, 2022, 434, 120156 Cognitive impairment and dementia in Parkinson's disease 2005, 657-663 13 The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes 2017, 211-224 12 O3-04-02: Clinico-Pathologic Correlations in Dementia with Lewy Bodies (DLB): A Prospective 11 Cohort Study 2016, 12, P291-P291 The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein & Allele Variant in Patients With Dementia. International Journal of Tryptophan 10 5.6 Research, 2019, 12, 1178646919885637

P3-243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM

NEUROPATHOLOGY 2018, 14, P1165-P1166

8	P1-523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI-C) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS 2018 , 14, P532-P532	
7	P1-151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE 2018 , 14, P335-P335	
6	P2-483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER 2018 , 14, P914-P914	
5	O1-10-04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY 2018 , 14, P244-P245	
4	P3-001: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA 2018 , 14, P1062-P1062	
3	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts - ERRATUM <i>British Journal of Psychiatry</i> , 2022 , 1-2	5.4
2	Specific depressive symptoms are related with different patterns of alcohol use in community-dwelling older adults <i>Archives of Gerontology and Geriatrics</i> , 2022 , 101, 104696	4
1	Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease <i>Health Science Reports</i> , 2022 , 5, e590	2.2